AbbVie

Goobra are a Danish company.

They have a very successful peptide-based drug development platform that has attracted the attention of several big pharma partners, most notably AbbVie last year, which licensed its amylin agonist for a very large upfront fee.

I have the Chief Executive of Goobra, Markus Rohrwild, and the Chief Development and Research Officer, I think I might have got that slightly

wrong.

Remember, it's not about just investing capital.

We have to be a good owner and we need to leverage what we have at Goobra to be a good owner of that asset.

So this acceleration, I'm sure, has been allowed by the large cash influx that you're getting from the AbbVie deal and the big Boehringer Ingelheim deals that you've had previously.

You did return a lot of that to investors through a special dividend.

Host Nora McNerney is back for an all-new season of The Head Start, Embracing the Journey, brought to you in partnership with AbbVie.

As Nora continues her conversations with people living with chronic migraine, she's also reconnecting with familiar voices from seasons past to see where they are now on their journey.

Of course, she'll be joined by headache specialist Dr. Christopher Ryan, who offers insight into these challenges and the questions that many of us have.

And again, as I said on Monday, what 44% of the S and P 500 reporting this week alone.

So there's just a, a, and again, we're just talking kind of, kind of some of the big, you know, headline numbers that are coming out, but there are literally just a plethora of companies reporting right now, all across the board from Feedport, Mac Moran to, um, you know, Eli Lilly to AbbVie, et cetera, so forth and so on.

Just a lot of companies reporting this week that will be kind of weighing on markets.

Yesterday, speaking of markets, we actually kind of did okay.

That's about a month ago, in fact, so it is quite fresh.

It will be marketed by the American company AbbVie.

Well, the story starts in a university lab.

The research behind it was pioneered by Dr. Richard Mailman, a professor of pharmacology and neuroscience at the University of Virginia, whose work on this new way of treating Parkinson's goes back more than 15 years.

So don't be surprised if I discover a major drug in coming years.

Juvmo was later developed by a company called Cerevel Therapeutics.

And AbbVie got it by acquiring Cerevel in a deal worth about $8.7 billion.

That's a lot of money.

And as an FYI for listeners, we've released a report that really is capturing 10 of the largest kind of players within healthcare.

And you've got payers and health services like a United and CVS, and then you've also got hospital systems like an HCA and a Tenet, and you've got a big distributor like a McKesson, and MedDevice being like an Abbott and Medtronic, and Pharma being Eli Lilly and AbbVie and JJ, right? You play almost every part.

You're talking to executives and leaders of those businesses.

I spent a lot of time in MedDevice, Pharma, and hospital system economics as well with some element of pay or two.

And hospitals and payers, as we've described, and distributors are all at that zero to 5% max average.

Now you've got these med device and pharma companies that are going to be on the whole other side of the distribution.

And so it's easy to look at the margins of an AbbVie or a J&J or the iLily or others and see these really fat margins of say 20 to 30, upwards of 35% net profit margins.

And it's really easy to go, how do you sleep at night living off the backs of the sick? But you get into their business and it's not easier looking at their business.

And again, as I said on Monday, what 44% of the S and P 500 reporting this week alone.

So there's just a, a, and again, we're just talking kind of, kind of some of the big, you know, headline numbers that are coming out, but there are literally just a plethora of companies reporting right now, all across the board from Feedport, Mac Moran to, um, you know, Eli Lilly to AbbVie, et cetera, so forth and so on.

Just a lot of companies reporting this week that will be kind of weighing on markets.

Yesterday, speaking of markets, we actually kind of did okay.

Ray's Marketplace is tackling future cybersecurity threats by developing quantum-proof encryption and blockchain tools to protect digital gift card systems.

In healthcare, Hollister scored a patent for flushable catheters made with eco-friendly biodegradable materials, while pharma giant AbbVie secured patents for less invasive Parkinson's treatments and continuous innovations around top-selling therapies like Renvox and Botox.

Handling massive computational strain is top of mind for Oceant, whose software enables ultra-fast analytics across petabytes of data, a necessity as artificial intelligence scales up computing demand.

Trading Technologies International and CME Group are also leveraging AI and low-latency matching engines to help traders manage tens of millions of data updates per second in an increasingly 24-7 financial market.